IRA, drug pricing in federal programs, biosimilars, orphan drugs, prescription drug access & reimbursement, FDA issues, transparency
2025 · 3rd Quarter (July 1 - Sep 30)
AMGEN INC
Filed by TARPLIN, DOWNS & YOUNG, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 15, 2025
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- TARPLIN, DOWNS & YOUNG, LLC
- Client
- AMGEN INC
- Filing UUID
- 02f793f4-f551-4295-866b-b4e31a0d68b9
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Medicare coverage and reimbursement issues, Medicare Part B reimbursement, transparency, prescription drug pricing and access, drug pricing in federal programs
federal budget issues
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.